Adalimumab/infliximab/rituximab

Various toxicities following off-label therapy: 5 case reports

    This is a preview of subscription content, log in to check access.

    Reference

    1. Dominguez-Casas LC, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Seminars in Arthritis and Rheumatism 50: 608-615, No. 4, Aug 2020. Available from: URL: http://doi.org/10.1016/j.semarthrit.2020.03.023

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Adalimumab/infliximab/rituximab. Reactions Weekly 1810, 16 (2020). https://doi.org/10.1007/s40278-020-80036-5

    Download citation